HENAN LINGRUI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.09 CNY | -7.46% |
|
-14.58% | +17.42% |
| 08-12 | Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 | CI |
| 05-13 | Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug | MT |
Projected Income Statement: Henan Lingrui Pharmaceutical Co., Ltd.
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,157 | - | 2,694 | 3,002 | 3,311 | 3,754 | 4,239 | 4,783 |
| Change | - | -100% | - | 11.45% | 10.31% | 13.35% | 12.92% | 12.85% |
| EBITDA 1 | - | - | 457.7 | 594.3 | 737 | 816.2 | 955.5 | 1,109 |
| Change | - | - | - | 29.83% | 24.02% | 10.75% | 17.06% | 16.1% |
| EBIT 1 | - | - | 435 | 517.1 | 656.3 | 772.1 | 913.4 | 1,070 |
| Change | - | - | - | 18.88% | 26.92% | 17.64% | 18.31% | 17.15% |
| Interest Paid | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | 413.4 | 517 | 653 | 794.1 | 936.4 | 1,094 |
| Change | - | - | - | 25.08% | 26.31% | 21.6% | 17.92% | 16.8% |
| Net income 1 | - | 325.5 | 361.5 | 465.3 | 568.1 | 693.5 | 817.8 | 955.2 |
| Change | - | - | 11.08% | 28.71% | 22.09% | 22.07% | 17.93% | 16.79% |
| Announcement Date | 20-04-28 | 21-04-28 | 22-04-25 | 23-04-25 | 24-04-25 | - | - | - |
1CNY in Million
Estimates
Forecast Balance Sheet: Henan Lingrui Pharmaceutical Co., Ltd.
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | -1,414 | -1,494 | -1,588 |
| Change | - | - | - | - | - | - | -205.66% | -206.29% |
| Announcement Date | 20-04-28 | 21-04-28 | 22-04-25 | 23-04-25 | 24-04-25 | - | - | - |
1CNY in Million
Estimates
Cash Flow Forecast: Henan Lingrui Pharmaceutical Co., Ltd.
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| CAPEX 1 | 14.77 | 11.04 | 40.5 | 40.5 | 40.5 |
| Change | - | -25.22% | 266.74% | 0% | 0% |
| Free Cash Flow (FCF) 1 | - | - | 622.3 | 738.9 | 857.8 |
| Change | - | - | - | 18.75% | 16.1% |
| Announcement Date | 23-04-25 | 24-04-25 | - | - | - |
1CNY in Million
Estimates
Forecast Financial Ratios: Henan Lingrui Pharmaceutical Co., Ltd.
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | - | 16.99% | 19.8% | 22.26% | 21.74% | 22.54% | 23.19% |
| EBIT Margin (%) | - | - | 16.15% | 17.23% | 19.82% | 20.57% | 21.55% | 22.37% |
| EBT Margin (%) | - | - | 15.35% | 17.22% | 19.72% | 21.15% | 22.09% | 22.87% |
| Net margin (%) | - | - | 13.42% | 15.5% | 17.16% | 18.48% | 19.29% | 19.97% |
| FCF margin (%) | - | - | - | - | - | 16.58% | 17.43% | 17.93% |
| FCF / Net Income (%) | - | - | - | - | - | 89.73% | 90.35% | 89.81% |
Profitability | ||||||||
| ROA | - | - | - | - | 11.91% | 13.4% | 14.81% | 16.14% |
| ROE | - | - | 15.92% | 19.28% | 21.28% | 23.43% | 25.48% | 27.33% |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | - | - | 0.49% | 0.33% | 1.08% | 0.96% | 0.85% |
| CAPEX / EBITDA (%) | - | - | - | 2.49% | 1.5% | 4.96% | 4.24% | 3.65% |
| CAPEX / FCF (%) | - | - | - | - | - | 6.51% | 5.48% | 4.72% |
Items per share | ||||||||
| Cash flow per share 1 | - | - | 1.49 | 1.471 | 1.434 | 1.147 | 1.419 | 1.658 |
| Change | - | - | - | -1.22% | -2.51% | -20.05% | 23.71% | 16.91% |
| Dividend per Share 1 | - | - | - | 0.6 | 0.8 | 0.9178 | 1.066 | 1.224 |
| Change | - | - | - | - | 33.33% | 14.72% | 16.1% | 14.86% |
| Book Value Per Share 1 | - | - | 4.014 | 4.495 | 4.921 | 5.271 | 5.724 | 6.253 |
| Change | - | - | - | 11.99% | 9.47% | 7.11% | 8.59% | 9.25% |
| EPS 1 | 0.512 | 0.573 | 0.638 | 0.819 | 1.003 | 1.226 | 1.44 | 1.682 |
| Change | - | 11.91% | 11.34% | 28.37% | 22.47% | 22.22% | 17.46% | 16.81% |
| Nbr of stocks (in thousands) | 567,809 | 567,809 | 564,553 | 564,253 | 563,938 | 563,162 | 563,162 | 563,162 |
| Announcement Date | 20-04-28 | 21-04-28 | 22-04-25 | 23-04-25 | 24-04-25 | - | - | - |
1CNY
Estimates
| 2024 * | 2025 * | |
|---|---|---|
| P/E ratio | 16.4x | 14x |
| PBR | 3.81x | 3.51x |
| EV / Sales | 2.64x | 2.32x |
| Yield | 4.57% | 5.3% |
More valuation ratios
* Estimated data
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
20.09CNY
Average target price
29.25CNY
Spread / Average Target
+45.59%
Annual profits - Rate of surprise
- Stock Market
- Equities
- 600285 Stock
- Financials Henan Lingrui Pharmaceutical Co., Ltd.
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition